BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Zhou L. Association between chronic hepatitis C infection and metabolic syndrome: A meta-analysis. Nutrition Clinique et Métabolisme 2022. [DOI: 10.1016/j.nupar.2022.03.002] [Reference Citation Analysis]
2 Tariq M, Shoukat AB, Akbar S, Hameed S, Naqvi MZ, Azher A, Saad M, Rizwan M, Nadeem M, Javed A, Ali A, Aziz S. Epidemiology, risk factors, and pathogenesis associated with a superbug: A comprehensive literature review on hepatitis C virus infection. SAGE Open Med 2022;10:20503121221105957. [PMID: 35795865 DOI: 10.1177/20503121221105957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gundling F. Der hepatogene Diabetes – aktueller Stand der Diagnostik und Therapie. J Klin Endokrinol Stoffw 2022;15:42-52. [DOI: 10.1007/s41969-022-00158-z] [Reference Citation Analysis]
4 Cabral LKD, Grisetti L, Pratama MY, Tiribelli C, Pascut D. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers (Basel) 2022;14:2700. [PMID: 35681679 DOI: 10.3390/cancers14112700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, Mantovani A, Serviddio G, Sacerdoti D. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience. J Dig Dis 2022;23:324-30. [PMID: 35700113 DOI: 10.1111/1751-2980.13103] [Reference Citation Analysis]
6 Yang C, Wan M, Lu Y, Yang X, Yang L, Wang S, Sun G. Associations between diabetes mellitus and the risk of hepatocellular carcinoma in Asian individuals with hepatitis B and C infection: systematic review and a meta-analysis of cohort studies. Eur J Cancer Prev 2022;31:107-16. [PMID: 35103624 DOI: 10.1097/CEJ.0000000000000669] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 García-Compeán D, Orsi E, Kumar R, Gundling F, Nishida T, Villarreal-Pérez JZ, Del Cueto-Aguilera ÁN, González-González JA, Pugliese G. Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World J Gastroenterol 2022; 28(8): 775-793 [DOI: 10.3748/wjg.v28.i8.775] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
9 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Isaac A, Elmarashly B, El Saeed K, Mohamed RS, Ibrahim SA, Safwat E. The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00110-x] [Reference Citation Analysis]
11 Yuan F, Hou L, Wei L, Quan R, Wang J, Liu H, Liu J. Fowl Adenovirus Serotype 4 Induces Hepatic Steatosis via Activation of Liver X Receptor-α. J Virol 2021;95:e01938-20. [PMID: 33361420 DOI: 10.1128/JVI.01938-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Johnson LP, Sterling RK. The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection. Biology (Basel) 2020;9:E87. [PMID: 32344543 DOI: 10.3390/biology9040087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Mogahed EA, Sayed AA, Khalifa SE, El-Hennawy A, El-Raziky MS. Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. Eur J Pediatr 2020;179:719-26. [PMID: 31897838 DOI: 10.1007/s00431-019-03551-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Adinolfi LE, Mangoni ED, Marrone A, Zampino R, Rinaldi L. Viral Hepatitis C. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_17] [Reference Citation Analysis]
16 Marei ES, Gabr HM, Shaheen DS. Potential role of vaspin and apelin in chronic hepatitis C virus patients with and without diabetes. Journal of Radiation Research and Applied Sciences 2020;13:155-163. [DOI: 10.1080/16878507.2020.1715556] [Reference Citation Analysis]
17 Gaggini M, Carli F, Rosso C, Younes R, D'Aurizio R, Bugianesi E, Gastaldelli A. Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. Int J Mol Sci 2019;20:E6333. [PMID: 31888144 DOI: 10.3390/ijms20246333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Makhlouf M, Saleh S, Rushdy M, Abdelhakam S, Abd-elghani E. Pentraxin-3 in non-alcoholic fatty liver disease and its affection by concomitant chronic hepatitis C infection. Egypt Liver Journal 2019;9:7. [DOI: 10.1186/s43066-019-0009-4] [Reference Citation Analysis]
19 Tian Y, Jennings J, Gong Y, Sang Y. Viral Infections and Interferons in the Development of Obesity. Biomolecules 2019;9:E726. [PMID: 31726661 DOI: 10.3390/biom9110726] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
20 Abudawood M. Diabetes and cancer: A comprehensive review. J Res Med Sci 2019;24:94. [PMID: 31741666 DOI: 10.4103/jrms.JRMS_242_19] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
21 Hu JH, Chang ML, Liu NJ, Yeh CT, Huang TJ. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. Exp Ther Med 2019;18:3568-78. [PMID: 31602234 DOI: 10.3892/etm.2019.7995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int J Mol Sci. 2019;20. [PMID: 31614690 DOI: 10.3390/ijms20205055] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 21.8] [Reference Citation Analysis]
23 Bender D, Hildt E. Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis. Int J Mol Sci 2019;20:E4659. [PMID: 31546975 DOI: 10.3390/ijms20184659] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
24 Alsebaey A, Elhelbawy M, Abdel-razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. Expert Review of Anti-infective Therapy 2019;17:749-54. [DOI: 10.1080/14787210.2019.1653184] [Reference Citation Analysis]
25 Alsebaey A, Elhelbawy M, Abdel-razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. Expert Review of Anti-infective Therapy 2019;17:749-754. [DOI: 10.1080/14787210.2019.1653184] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
26 Elfayoumy KN, Berengy MS, Emran T. Insulin/high-density lipoprotein cholesterol ratio: A newly-discovered predictor of esophageal varices in patients with hepatitis C virus-related cirrhosis in the absence of diabetes mellitus. Turk J Gastroenterol 2019;30:155-62. [PMID: 30541737 DOI: 10.5152/tjg.2018.18237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Li Y, Wang X, Yu G, Sun H, Lv J, Chi X, Wu R, Gao X, Niu J. The association of hepatitis c virus infection status with serum glucose levels. BMC Gastroenterol. 2019;19:86. [PMID: 31195990 DOI: 10.1186/s12876-019-1003-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Duerr M, Schrezenmeier EV, Lehner LJ, Bergfeld L, Glander P, Marticorena Garcia SR, Althoff CE, Sack I, Brakemeier S, Eckardt KU, Budde K, Halleck F. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. BMC Nephrol 2019;20:36. [PMID: 30717681 DOI: 10.1186/s12882-019-1218-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
29 van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of Non-Alcoholic Fatty Liver Disease in HIV-infected patients: The next big thing? Infect Dis Ther. 2019;8:33-50. [PMID: 30607807 DOI: 10.1007/s40121-018-0229-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
30 Villar LM, Villela-nogueira CA, Silva APD, Scalioni LP. Metabolic Factors and Their Influence on the Clinical Course and Response to HCV Treatment. Hepatitis C - From Infection to Cure 2018. [DOI: 10.5772/intechopen.77387] [Reference Citation Analysis]
31 Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 2018;68:904-11. [PMID: 29233630 DOI: 10.1016/j.jhep.2017.12.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
32 Prasad B, Bhatt DK, Johnson K, Chapa R, Chu X, Salphati L, Xiao G, Lee C, Hop CECA, Mathias A, Lai Y, Liao M, Humphreys WG, Kumer SC, Unadkat JD. Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. Drug Metab Dispos 2018;46:943-52. [PMID: 29695616 DOI: 10.1124/dmd.118.080523] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
33 Zhang P, Meng L, Song L, Du J, Du S, Cui W, Liu C, Li F. Roles of Perilipins in Diseases and Cancers. Curr Genomics 2018;19:247-57. [PMID: 29755288 DOI: 10.2174/1389202918666170915155948] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
34 Li X, Wang X, Gao P. Diabetes Mellitus and Risk of Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:5202684. [PMID: 29379799 DOI: 10.1155/2017/5202684] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
35 Parra M, Laufer N, Manrique JM, Jones LR, Quarleri J. Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients. Biomed Res Int 2017;2017:1728456. [PMID: 29259976 DOI: 10.1155/2017/1728456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Bilić-ćurčić I, Roguljić H, Ivandić M, Včev A, Smolić R, Smolić M. Hepatitis C–Associated Diabetes Mellitus. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70721] [Reference Citation Analysis]
37 Jukić LV, Kralj D. Extrahepatic Manifestations of Hepatitis C Virus Infection. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Voss JD, Dhurandhar NV. Viral Infections and Obesity. Curr Obes Rep 2017;6:28-37. [PMID: 28290153 DOI: 10.1007/s13679-017-0251-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
39 Wong RJ, Saab S, Ahmed A. Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation. Clin Liver Dis 2017;21:595-606. [PMID: 28689596 DOI: 10.1016/j.cld.2017.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Davis TME, Davis WA, Jeffrey G. Successful Withdrawal of Insulin Therapy After Post-Treatment Clearance of Hepatitis C Virus in a Man with Type 2 Diabetes. Am J Case Rep 2017;18:414-7. [PMID: 28413215 DOI: 10.12659/ajcr.903600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Li X, Xu H, Gao Y, Pan M, Wang L, Gao P. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine (Baltimore) 2017;96:e6508. [PMID: 28353605 DOI: 10.1097/MD.0000000000006508] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
42 Zhao Y, Xing H. A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases. J Diabetes Res 2017;2017:5625371. [PMID: 28352640 DOI: 10.1155/2017/5625371] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
43 Manickam C, Wachtman L, Martinot AJ, Giavedoni LD, Reeves RK. Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus). PLoS One 2017;12:e0170240. [PMID: 28085952 DOI: 10.1371/journal.pone.0170240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
44 Awad A, Gassama-Diagne A. PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis. World J Hepatol 2017; 9(1): 18-29 [PMID: 28105255 DOI: 10.4254/wjh.v9.i1.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
45 Nirei K, Matsumura H, Kumakawa M, Matsumoto N, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci 2017;14:45-52. [PMID: 28138308 DOI: 10.7150/ijms.17202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
46 Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Medicina Clínica (English Edition) 2017;148:78-85. [DOI: 10.1016/j.medcle.2016.09.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Stevenson HL, Utay NS. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Trop Dis Travel Med Vaccines 2016;2:21. [PMID: 28883965 DOI: 10.1186/s40794-016-0038-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
48 Rebbani K, Tsukiyama-Kohara K. HCV-Induced Oxidative Stress: Battlefield-Winning Strategy. Oxid Med Cell Longev. 2016;2016:7425628. [PMID: 27293514 DOI: 10.1155/2016/7425628] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]